A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice

PLoS Neglected Tropical Diseases

Volumn 8, Issue 7, 2014, Pages

  Weger Lucarelli, James ^a   Chu, Haiyan ^b   Aliota, Matthew T ^a   Partidos, Charalambos D ^b   Osorio, Jorge E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Takeda Vaccines Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; E2 PROTEIN; E3 PROTEIN; GAMMA INTERFERON; MODIFIED VACCINIA VIRUS ANKARA VECTOR; NEUTRALIZING ANTIBODY; PEPTIDES AND PROTEINS; PROTEIN P62; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOOT PAD; HISTOPATHOLOGY; IMMUNITY; IMMUNOCYTOCHEMISTRY; IMMUNOGENICITY; MORTALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; SEROLOGY; T CELL DEPLETION; VACCINATION; VIREMIA; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; GENE VECTOR; GENETICS; IMMUNOLOGY; VACCINIA VIRUS; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; GENETIC VECTORS; MICE; MICE, INBRED BALB C; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84905444576     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002970     Document Type: Article

References (83)

1. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, et al. (2007) Outbreak of Chikungunya on Reunion Island: Early clinical and laboratory features in 157 adult patients. Clinical Infectious Diseases 44: 1401-1407.
2. Centers for Disease C, Prevention (2012) Chikungunya outbreak-Cambodia, February-March 2012. MMWR Morb Mortal Wkly Rep 61: 737-740.
3. Rianthavorn P, Prianantathavorn K, Wuttirattanakowit N, Theamboonlers A, Poovorawan Y, (2010) An outbreak of chikungunya in southern Thailand from 2008 to 2009 caused by African strains with A226V mutation. Int J Infect Dis 14 Suppl 3: e161-165.
4. Powers AM, (2011) Genomic evolution and phenotypic distinctions of Chikungunya viruses causing the Indian Ocean outbreak. Exp Biol Med (Maywood) 236: 909-914.
5. Tomasello D, Schlagenhauf P, (2013) Chikungunya and dengue autochthonous cases in Europe, 2007-2012. Travel Med Infect Dis 11: 274-284.
6. Tsetsarkin KA, Weaver SC, (2011) Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence. PLoS Pathog 7: e1002412.
7. Pialoux G, Gauzere BA, Strobel M, (2006) [Chikungunya virus infection: review through an epidemic]. Med Mal Infect 36: 253-263.
8. Tsetsarkin KA, McGee CE, Volk SM, Vanlandingham DL, Weaver SC, et al. (2009) Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. PLoS One 4: e6835.
9. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S, (2007) A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 3: e201.
10. Robinson MC, (1956) An epidemic of a dengue-like fever in the southern province of Tanganyika. Cent Afr J Med 2: 394-396.
11. Powers AM, Logue CH, (2007) Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88: 2363-2377.
12. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, et al. (2000) Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 62: 681-685.
13. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE Jr, et al. (1986) Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4: 157-162.
14. Khan M, Dhanwani R, Rao PV, Parida M, (2012) Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res 167: 236-246.
15. Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, et al. (2012) Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 30: 4638-4643.
16. Wang E, Kim DY, Weaver SC, Frolov I, (2011) Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response. J Virol 85: 9249-9252.
17. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, et al. (2011) Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 7: e1002142.
18. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, et al. (2010) A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 16: 334-338.
19. Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, et al. (2011) A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 29: 2803-2809.
20. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, et al. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80: 148-158.
21. Mayr A, Stickl H, Muller HK, Danner K, Singer H, (1978) The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol B 167: 375-390.
22. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, et al. (1974) MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl). Dtsch Med Wochenschr 99: 2386-2392.
23. Mayr A, Munz E, (1964) Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralbl Bakteriol Orig 195: 24-35.
24. Antoine G, Scheiflinger F, Dorner F, Falkner FG, (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
25. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B, (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12: 1032-1040.
26. Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, et al. (2002) Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 346: 1265-1274.
27. Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr, (2004) Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. J Infect Dis 189: 1401-1410.
28. Wedman EE, Smith AW, Oliver RE, (1988) Immunogenicity, pathogenicity, and transmissibility of a recombinant vaccinia virus in calves. Am J Vet Res 49: 2018-2021.
29. Franke CA, Berry ES, Smith AW, Hruby DE, (1985) Immunisation of cattle with a recombinant togavirus-vaccinia virus strain. Res Vet Sci 39: 113-115.
30. Kinney RM, Esposito JJ, Mathews JH, Johnson BJ, Roehrig JT, et al. (1988) Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol 62: 4697-4702.
31. Kinney RM, Esposito JJ, Johnson BJ, Roehrig JT, Mathews JH, et al. (1988) Recombinant vaccinia/Venezuelan equine encephalitis (VEE) virus expresses VEE structural proteins. J Gen Virol 69 (Pt 12) (): 3005-3013.
32. Sviatchenko VA, Kiselev NN, Ryzhikov AB, Bulychev LE, Mikriukova TP, et al. (2000) Immunogenicity of a recombinant strain of vaccinia virus, expressing a Venezuelan equine encephalomyelitis virus structural protein gene in peroral immunization. Vopr Virusol 45: 38-41.
33. Sviatchenko VA, Agapov EV, Urmanov I, Serpinskii OI, Frolov IV, et al. (1993) [The immunogenic properties of a recombinant vaccinia virus with an incorporated DNA copy of the 26S RNA of the Venezuelan equine encephalomyelitis virus]. Vopr Virusol 38: 222-226.
34. Paessler S, Yun NE, Judy BM, Dziuba N, Zacks MA, et al. (2007) Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. Virology 367: 307-323.
35. Brooke CB, Deming DJ, Whitmore AC, White LJ, Johnston RE, (2010) T cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody. J Virol 84: 4556-4568.
36. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, Contreras ML, Padilla S, et al. (2006) Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13: 592-597.
37. Brewoo JN, Powell TD, Stinchcomb DT, Osorio JE, (2010) Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice. Vaccine 28: 5891-5899.
38. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, et al. (2006) Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24: 4554-4561.
39. Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, et al. (2004) A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 1: e33.
40. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M, (2011) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11: 189-217.
41. Gomez CE, Perdiguero B, Garcia-Arriaza J, Esteban M, (2013) Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines 12: 1395-1416.
42. Cottingham MG, Carroll MW, (2013) Recombinant MVA vaccines: dispelling the myths. Vaccine 31: 4247-4251.
43. Hanke T, McMichael AJ, Dennis MJ, Sharpe SA, Powell LA, et al. (2005) Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23: 1507-1514.
44. Volz A, Sutter G, (2013) Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies. Vaccine 31: 4235-4240.
45. Garcia-Arriaza J, Cepeda V, Hallengard D, Sorzano CO, Kummerer BM, et al. (2014) A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection. J Virol 88: 3527-3547.
46. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, et al. (2008) A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4: e29.
47. Gardner CL, Burke CW, Higgs ST, Klimstra WB, Ryman KD, (2012) Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate. Virology 425: 103-112.
48. Orozco S, Schmid MA, Parameswaran P, Lachica R, Henn MR, et al. (2012) Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol 93: 2152-2157.
49. Lum FM, Teo TH, Lee WW, Kam YW, Renia L, et al. (2013) An essential role of antibodies in the control of Chikungunya virus infection. J Immunol 190: 6295-6302.
50. Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, et al. (2013) Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 31: 3353-3360.
51. Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, et al. (2011) Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine 29: 3067-3073.
52. Roy CJ, Adams AP, Wang E, Plante K, Gorchakov R, et al. (2014) Chikungunya Vaccine Candidate is Highly Attenuated and Protects Nonhuman Primates Against Telemetrically-monitored Disease Following a Single Dose. J Infect Dis 209: 1891-1899.
53. Brewoo JN, Powell TD, Jones JC, Gundlach NA, Young GR, et al. (2013) Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine 31: 1848-1855.
54. Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, et al. (2012) Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med 4: 330-343.
55. Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, et al. (2012) Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol 86: 13005-13015.
56. Snyder AJ, Mukhopadhyay S, (2012) The alphavirus E3 glycoprotein functions in a clade-specific manner. J Virol 86: 13609-13620.
57. Chakrabarti S, Sisler JR, Moss B, (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23: 1094-1097.
58. Sutter G, Moss B, (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89: 10847-10851.
59. Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW, (2001) Preparation of cell cultures and vaccinia virus stocks. Curr Protoc Protein Sci Chapter 5: Unit5 12.
60. Earl PL, Moss B, Wyatt LS, Carroll MW, (2001) Generation of recombinant vaccinia viruses. Curr Protoc Protein Sci Chapter 5: Unit5 13.
61. Staib C, Drexler I, Sutter G, (2004) Construction and isolation of recombinant MVA. Methods Mol Biol 269: 77-100.
62. Gomez CE, Perdiguero B, Cepeda MV, Mingorance L, Garcia-Arriaza J, et al. (2013) High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome. J Virol 87: 7282-7300.
63. Song F, Fux R, Provacia LB, Volz A, Eickmann M, et al. (2013) Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 87: 11950-11954.
64. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, et al. (2004) Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428: 182-185.
65. Grosfeld H, Velan B, Leitner M, Cohen S, Lustig S, et al. (1989) Semliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challenge. J Virol 63: 3416-3422.
66. Messaoudi I, Vomaske J, Totonchy T, Kreklywich CN, Haberthur K, et al. (2013) Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity. PLoS Negl Trop Dis 7: e2343.
67. Gardner J, Anraku I, Le TT, Larcher T, Major L, et al. (2010) Chikungunya virus arthritis in adult wild-type mice. J Virol 84: 8021-8032.
68. Kumar M, Sudeep AB, Arankalle VA, (2012) Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30: 6142-6149.
69. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT, (2012) Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 11: 1087-1101.
70. Garber DA, O'Mara LA, Gangadhara S, McQuoid M, Zhang X, et al. (2012) Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86: 12605-12615.
71. Hodgson LA, Ludwig GV, Smith JF, (1999) Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors. Vaccine 17: 1151-1160.
72. Griffin D, Levine B, Tyor W, Ubol S, Despres P, (1997) The role of antibody in recovery from alphavirus encephalitis. Immunol Rev 159: 155-161.
73. Boere WA, Benaissa-Trouw BJ, Harmsen M, Kraaijeveld CA, Snippe H, (1983) Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis. J Gen Virol 64 (Pt 6) (): 1405-1408.
74. Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson ED, (1999) Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus. Vaccine 18: 588-596.
75. Metz SW, Geertsema C, Martina BE, Andrade P, Heldens JG, et al. (2011) Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells. Virol J 8: 353.
76. Cutler DF, Garoff H, (1986) Mutants of the membrane-binding region of Semliki Forest virus E2 protein. I. Cell surface transport and fusogenic activity. J Cell Biol 102: 889-901.
77. Barth BU, Garoff H, (1997) The nucleocapsid-binding spike subunit E2 of Semliki Forest virus requires complex formation with the E1 subunit for activity. J Virol 71: 7857-7865.
78. Metz SW, van den Doel P, Geertsema C, Osterhaus AD, Vlak JM, et al. (2013) Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 31: 6092-6096.
79. Yun NE, Peng BH, Bertke AS, Borisevich V, Smith JK, et al. (2009) CD4+ T cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus. Vaccine 27: 4064-4073.
80. Teo TH, Lum FM, Claser C, Lulla V, Lulla A, et al. (2013) A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice. J Immunol 190: 259-269.
81. Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, et al. (2013) Chronic joint disease caused by persistent chikungunya virus infection is controlled by the adaptive immune response. J Virol 87: 13878-13888.
82. Hoarau JJ, Gay F, Pelle O, Samri A, Jaffar-Bandjee MC, et al. (2013) Identical Strength of the T Cell Responses against E2, nsP1 and Capsid CHIKV Proteins in Recovered and Chronic Patients after the Epidemics of 2005-2006 in La Reunion Island. PLoS One 8: e84695.
83. Garcia-Arriaza J, Cepeda V, Hallengard D, Sorzano CO, Kummerer BM, et al. (2014) A Novel Poxvirus-based Vaccine (MVA-CHIKV) is Highly Immunogenic and Protects Mice against Chikungunya Infection. J Virol 88: 3527-3547.